AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets
AbbVie is partnering with Disco Pharmaceuticals, a preclinical cancer biotech, to build out its antibody-drug conjugate and T cell engager programs.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







